[HTML][HTML] Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis

AP Espejo-Freire, A Elliott, A Rosenberg, PA Costa… - Cancers, 2021 - mdpi.com
Simple Summary Angiosarcomas (AS) are rare, highly aggressive sarcomas with limited
therapeutic options. Genomic sequencing techniques have identified recurrent genetic …

[HTML][HTML] Giant bullous emphysema mistaken for traumatic pneumothorax

EGF Junior, PA Costa, LMFG Silveira… - International journal of …, 2019 - Elsevier
Introduction: Giant bullous emphysema (GBE) is defined by giant bullae in one or both upper
lobes, occupying at least one-third of the hemithorax and compressing the surrounding …

[HTML][HTML] Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma

PA Costa, DT Tse, P Benedetto - The Oncologist, 2024 - academic.oup.com
Background Lacrimal gland adenoid cystic carcinoma (LGACC) has historically been
associated with a poor prognosis even with localized disease, with a survival of 56% at 5 …

Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate

PA Costa, AP Espejo-Freire, KC Fan… - Leukemia & …, 2022 - Taylor & Francis
Brentuximab vedotin (BV) is an antibody-drug conjugate composed of an anti-CD30
monoclonal antibody conjugated through a linker to the microtubule disturbing agent …

A nonrandom association of breast implants and the formation of desmoid tumors

PA Costa, S Marbin, BMLA Costa… - The breast …, 2021 - Wiley Online Library
Background Studies suggest that surgical breast augmentation with implants is a risk factor
for breast desmoid tumors. The statistical strength of this correlation is unknown, as …

Clinical attributes and outcomes in metastatic non-small cell lung cancer bearing BRAF mutations treated with targeted therapy versus immunotherapy.

R Dawar, K Gawri, E Rodriguez, D Kwon, F Basher… - 2021 - ascopubs.org
e21219 Background: Mutations in BRAF oncogene have been identified in about 2-4% of
non-small cell lung cancer (NSCLC) patients. Combination of tyrosine kinase inhibitors …

KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.

S Bialick, BE Rose, AP Espejo-Freire, P Barreto Coelho… - 2022 - ascopubs.org
11514 Background: Tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for
advanced GIST via pharmacologic targeting of driver oncogenes such as KIT. Detection of …

[PDF][PDF] Clinical outcomes of cancer patients with COVID-19: A systematic review and meta-analysis

M Alasfour, S Alawadi, M AlMojel… - Journal of Clinical …, 2021 - posterpresentations.com
• Initial Comprehensive search yielded 2,618 studies. After excluding duplicates and those
that do not meet inclusion criteria, 34 studies were included in the final analysis. That brings …

[HTML][HTML] Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: A report of two cases

PA Costa, CKA Hana, NC Balaji… - Gastrointestinal …, 2021 - gist.amegroups.org
Despite an initial response, most metastatic gastrointestinal stromal tumor (GIST) patients
will ultimately be refractory to all current therapies, including imatinib, sunitinib, and …

[HTML][HTML] Transhiatal esophagectomy with gastric pull-up, pyloric exclusion and Roux-en-Y gastroenterostomy for the management of esophageal caustic injury

EGF Junior, PA Costa, LMFG Silveira… - International journal of …, 2019 - Elsevier
Introduction Ingestion of caustic materials can lead to digestive tube perforation involving the
mouth, pharynx, esophagus and stomach (Vezakis et al., 2016 [1]). In this case report, the …